SignalXSignalX

MAZE Maze Therapeutics, Inc.

FY2024 10-K
Filed: Mar 31, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR
Maze Therapeutics, Inc. Overview

Maze Therapeutics, Inc. (MAZE) filed its fiscal year 2024 10-K annual report with the SEC on Mar 31, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Business Overview

  • • Core business: Genetic medicine focused on novel drug discovery for complex diseases
  • • No new products, services, or segments introduced or emphasized in FY 2025 filing
+3 more insights

Management Discussion & Analysis

  • • Revenue $167.5M in 2024 vs $0 in 2023 from license agreements with Shionogi, Trace, Neurocrine
  • • Net income $52.2M in 2024 vs net loss $100.4M in 2023; operating margin approx. 33.3% (income from operations $57.6M / revenue $167.5M) in 2024 vs negative in 2023
+3 more insights

Risk Factors

  • • No specific regulatory or legal risk disclosed in the section
  • • No geopolitical or macroeconomic threat detailed in the section
+3 more insights

Get deeper insights on Maze Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available